有业内人士表示，赛分科技扬州二期工程将进一步强化对合作伙伴的服务能力，提升规模化交付效率，持续提供稳定可靠 的产品及配套服务，为合作伙伴各项目稳定生产与产能扩张保驾护航。同时，伴随中国生物制药出海浪潮，该项目也将助力公 司推进海外市场拓展战略，进一步扩大赛分科技在全球色谱层析市场的影响力。 （编辑 郭之宸） 据悉，作为国产色谱填料龙头企业，赛分科技深度参与中国生物医药行业快速发展及供应链国产化进程，在抗体、胰岛 素、GLP-1等多肽药物、重组蛋白、核酸药物等生物药细分领域积累了广泛应用项目，其中临床后期及商业化项目数量超百 个。公司与生物药各领域标杆企业紧密合作，部分重点项目中填料单次供货量超千升，最大达4000升，Protein A亲和、定制亲 和、阴阳离子交换、疏水等填料的装柱规模均达到2000mm。面对持续增长的色谱填料规模化供应需求，扬州二期项目配置 5000L最大反应釜，单批次产能超1000L，同时升级自动化生产管理系统与质量管理系统，将进一步提升赛分科技色谱填料规模 化供应能力及产品质量管理水平。 赛分科技自上市以来，业务发展态势强劲。2025年前三季度，公司实现营业收入3.02亿元，同比增长38 ...

近期，中国生物医药行业发展迅速，夏尔巴生物成功完成全国首批2万升规模抗体生产，信达生物达成 重磅BD交易，加速迈向全球市场，甘李药业签署巴西国家级《技术转移与供应协议》，百奥泰 Usymro®获欧盟委员会上市批准，安睿特重组人白蛋白注射液Ⅲ期临床试验完成揭盲，这些赛分科技合 作伙伴的商业化能力不断加强，意味着对高性能表现、大规模供应、高质量水平的国产色谱填料的需求 也将迅速和持续增加。赛分科技扬州二期工程将更好地服务合作伙伴，提升规模化交付能力，持续提供 稳定可靠的产品和配套服务，为合作伙伴各项目的稳定生产和产能增长保驾护航。同时，伴随着中国生 物制药的出海大潮，扬州二期工程也将支持公司扩展海外市场的发展战略，扩大赛分科技在全球色谱层 析市场的影响力。（齐和宁） 赛分科技于今年一月登陆科创板，上市以来，整体业务发展态势强劲，2025年前三季度实现营业收入 3.02亿元，同比增长38.39%，归属于上市公司股东的净利润9321.18万元，同比增长71.07%，其中，工 业纯化板块增长尤为显著，2025年前三季度收入同比增长68.08%。在产能布局方面，作为上市募投项 目的扬州二期工程已全面启动建设，这一举措不仅 ...

Core Insights - The biopharmaceutical industry is accelerating commercialization processes, significantly boosting the demand for chromatography materials due to multiple innovative drug projects entering production stages [1] - The company, Saifen Technology, has achieved dual breakthroughs in performance and technical strength, with its industrial purification business being the main growth driver [2] - The company has made significant advancements in core technologies, enhancing its product offerings and establishing itself as an industry benchmark [4] Industry Overview - The demand for chromatography consumables is surging, driven by the expansion of GLP-1 drugs and recombinant proteins, creating vast growth opportunities for Saifen Technology [1] - The industrial purification sector has shown remarkable performance, with sales revenue reaching 120 million yuan, a year-on-year increase of 28.59%, accounting for 65.97% of total revenue [2] - The company has completed 87 clinical phase III and commercialization projects for imported filler replacements, with a focus on antibodies, GLP-1, and recombinant proteins [6] Company Performance - In the first half of 2025, Saifen Technology reported a revenue of 183 million yuan, a year-on-year growth of 19.76%, with a gross margin of 70.60% [5] - The net profit attributable to the parent company reached 53.66 million yuan, up 40.91% year-on-year, with a net profit excluding non-recurring items of 46.50 million yuan, reflecting a growth of 22.08% [5] - The company has expanded its customer base and increased sales to significant clients, with sales exceeding 10 million yuan contributing to 86.22% of the industrial purification revenue [2] Technological Advancements - Saifen Technology has upgraded its core technology platforms, launching new industrial purification products, including high-performance affinity and cation exchange fillers [4] - The company has achieved precise control over microsphere synthesis and developed surface modification techniques to enhance product performance [4] - The introduction of a new generation of size exclusion chromatography columns supports global business expansion and solidifies the company's position among top international chromatography firms [3] Future Outlook - Saifen Technology plans to increase R&D investment, deepen chromatography technology, and continue launching innovative products to enhance performance and quality [6] - The company aims to accelerate the domestic substitution process and strengthen collaborations with domestic pharmaceutical companies to expand market share [6] - The completion of the second phase of the Yangzhou project will enable an annual production capacity of over 200,000 liters of chromatography media, supporting domestic substitution and pharmaceutical growth demands [6]